<DOC>
	<DOCNO>NCT00241371</DOCNO>
	<brief_summary>To determine overall response rate ( CR+PR ) patient relapse refractory multiple myeloma treat clofarabine .</brief_summary>
	<brief_title>A Phase II Study Clofarabine Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>To determine time response , duration response , time progression patient treat clofarabine . To determine safety tolerability clofarabine patient .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>1 . Multiple myeloma diagnose standard criterion . 2 . Measurable level monoclonal protein serum ( &gt; = 0.5 g/dL ) urine ( &gt; = 0.2 g/24 hr ) . 3 . At least 1 prior therapy multiple myeloma document evidence progression recent treatment . 4 . Age 18 year old . 5 . ECOG performance status &lt; = 2 . 6 . Acceptable organ marrow function define : Hemoglobin &gt; = 8 gm/dL Absolute neutrophil count &gt; = 1,000/mm3 Platelets &gt; = 50,000/mm3 Total bilirubin &lt; = 2.5 X institutional upper limit normal AST , ALT &lt; = 2.5 X institutional upper limit normal Creatinine 1.5 x institutional upper limit normal Normal cardiac function determine standard institutional method 7 . Women child bear potential must agree use adequate contraception prior study entry duration study . 8 . Ability understand willingness sign write informed consent document . 1 . Receiving investigational agent . 2 . Receiving concurrent steroid dose equivalent prednisone &gt; = 150 mg/month . 3 . Pregnant nursing . 4 . Active systemic infection consider opportunistic , life threaten clinically significant time treatment . 5 . Severe concurrent disease , include severe insulindependent diabetes , uncontrolled hypertension , transient ischemic attack , uncontrolled symptomatic coronary artery disease , symptomatic CNS involvement psychiatric illness/social situation would limit compliance study requirement . 6 . History malignancy except basal cell squamous cell carcinoma skin carcinoma situ cervix breast unless subject treatment free disease &gt; = 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
</DOC>